Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 52-58

  Winget, Marcy ^a,b   Fleming, John ^a   Li, Xue ^a   Gao, Zhiwei ^b   Butts, Charles ^a  

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adjuvant chemotherapy; Consultation; Early stage NSCLC; Survival; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; DRUG INTOXICATION; DRUG WITHDRAWAL; FEMALE; FRAIL ELDERLY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ALBERTA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79952185841     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.07.005     Document Type: Article

References (20)

1. American Cancer Society Cancer facts & figures 2009.
2. Scott W.J., Howington J., Feigenberg S., Movsas B., Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S.
3. Fry W., Phillips J.L., Menck H.R. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. A National Cancer Data Base Report. Cancer 1999, 86:1867-1876.
4. Winton T., Livingston R., Johnson D., Rigas J., Johnson M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
5. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzáles-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:19-27.
6. Arriagada R., Bergman B., Dunant A., Le C.T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
7. Winget M., Stanger J., Gao Z., Butts C. Predictors of surgery and consult with an oncologist for adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. J Thorac Oncol 2009, 4:629-634.
8. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Record Layout Version 12 2009, North American Association of Central Cancer Registries, Springfield, IL.
9. Deddens J.A., Peterson M.R. Approaches for estimating prevalence ratios. Occup Environ Med 2008, 65:501-506.
10. Harrell F.E. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis 2001, Springer, New York.
11. Schrag D., Cramer L.D., Bach P.B., Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001, 93:850-857.
12. Ayanian J.Z., Zaslavsky A.M., Fuchs C.S., Guadagnoli E., Creech C.M., Cress R.D., et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003, 21:1293-1300.
13. Cree M., Tonita J., Turner D., Nugent Z., Alvi R., Barss R., et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan and Manitoba in 2004. Clin Colorectal Cancer 2009, 8(3):141-145.
14. Winget M, Hossain S, Yasui Y, Scarfe A. Characteristics of stage III colon adenocarcinoma patients who fail to receive guideline-recommended treatment. Cancer, [published online in advance of print 24 June 2010]. doi:10.1002/cncr.25250.
15. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients. 2006 ASCO annual meeting proceedings, Part I. J Clin Oncol 2006, 24(18S):7008.
16. Strauss G.M., Herndon J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006, 24(18S):7007.
17. Pisters K.M.W., Evans W.K., Azzoli C.G., Kris M.G., Smith C.A., Desch C.E., et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer Guideline. J Clin Oncol 2007, 25(24):1-13.
18. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002, 94:173-181.
19. Rocha Lima C.M., Herndon J.E., Kosty M., Clamon G., Green M.R. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002, 94:181-187.
20. Alam N., Shepherd F.A., Winton T., Graham B., Johnson D., Livingston R., et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 2005, 47:385-394.